Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40 results about "Guillain-Barre syndrome" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Guillain-Barre syndrome is a rare condition in which your immune system attacks your nerves, leading to muscle weakness and even paralysis.
Substituted aryl amides
Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK & CO INC
Substituted amides
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Substituted amides
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Substituted 2,3-diphenyl pyridines
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Compositions and methods for the prevention or treatment of pain and other nervous system disorders
A tolperisone-related compound or a compound of Formula Z is administered for the prevention and treatment of periodic paralyses and myotonias of several types, long QT syndrome, Brugada syndrome, malignant hyperthermia, myasthenia, epilepsy, ataxia, migraine, Alzheimer's Disease, Parkinson's Disease, schizophrenia, and hyperekplexia, neuropathic pain, and pain associated with nervous system disorders including, but not limited to, painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, complex regional pain syndrome, Guillain-Barre syndrome (GBS), Charcot-Marie-Tooth (CMT) disease, complex regional pain syndrome, type 1 (CRPS-1), ischemic neuropathy, fibromyalgia, chronic fatigue syndrome, painful spasticities, and other nervous system disorders that have pain as an attendant sign and / or symptom.
Owner:SPEICHER BRIAN T +1
Substituted pyrimidines
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Bicyclic amides
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Substituted pyrimidines
Owner:MERCK SHARP & DOHME CORP
Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Substituted 2,3-diphenyl pyridines
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Substituted furo[2,3-b]pyridine derivatives
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
![Substituted furo[2,3-b]pyridine derivatives](https://images-eureka.patsnap.com/patent_img/c9b9cc4e-0710-4977-a22c-471a25d75136/US07091216-20060815-C00001.png "Substituted furo[2,3-b]pyridine derivatives")
![Substituted furo[2,3-b]pyridine derivatives](https://images-eureka.patsnap.com/patent_img/c9b9cc4e-0710-4977-a22c-471a25d75136/US07091216-20060815-C00002.png "Substituted furo[2,3-b]pyridine derivatives")
![Substituted furo[2,3-b]pyridine derivatives](https://images-eureka.patsnap.com/patent_img/c9b9cc4e-0710-4977-a22c-471a25d75136/US07091216-20060815-C00003.png "Substituted furo[2,3-b]pyridine derivatives")
Owner:MERCK SHARP & DOHME CORP
Combinant polypeptide for use in the manufacture of vaccines against Campylobacter induced diarrhea and to reduce colonization
This invention comprises a recombinant protein comprising the maltose binding protein (MBP) of Escherichia coli fused to amino acids 5–337 of the FlaA flagellin of Campylobacter coli VC167 which has provided evidence of immunogenicity and protective efficacy against challenge by a heterologous strain of campylobacter, Campylobacter jejuni 81–176 in mammals. The invention further comprises a recombinant DNA construct encoding the immunodominant region (region I through III) of flagellin from Campylobacter spp. for use as a component of a vaccine against Campylobacter diarrhea. The invention therefore represents an effective treatment against Campylobacter but avoids inducing the autoimmune Guillain Barre Syndrome (GBS), a post-infection polyneuropathy caused by Campylobacter molecular mimicry of human gangliosides which has hampered the development of vaccines heretofore.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY
Substituted furo[2,3-b]pyridine derivatives
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
![Substituted furo[2,3-b]pyridine derivatives](https://images-eureka.patsnap.com/patent_img/3ed63723-40f5-4ba6-aa1b-8315990b9ddc/US20050272763A1-20051208-C00001.png "Substituted furo[2,3-b]pyridine derivatives")
![Substituted furo[2,3-b]pyridine derivatives](https://images-eureka.patsnap.com/patent_img/3ed63723-40f5-4ba6-aa1b-8315990b9ddc/US20050272763A1-20051208-C00002.png "Substituted furo[2,3-b]pyridine derivatives")
![Substituted furo[2,3-b]pyridine derivatives](https://images-eureka.patsnap.com/patent_img/3ed63723-40f5-4ba6-aa1b-8315990b9ddc/US20050272763A1-20051208-C00003.png "Substituted furo[2,3-b]pyridine derivatives")
Owner:MERCK SHARP & DOHME CORP
Method for shunting toxic substances from a brain ventricle to the sinus system
InactiveUS20070112293A1Reduce concentrationIncrease productionWound drainsIntravenous devicesGuillain-Barre syndromePolymyositis-Dermatomyositis
The present invention is directed to methods for controlled and optimized removal of cerebrospinal fluid (CSF) from the CSF space of a patient. The methods are particularly intended for the treatment of Alzheimer's disease and other conditions which are caused by, or otherwise related to, the retention and / or accumulation of toxic substances in the CSF. One aspect of the present invention provides a method for shunting toxic substances present in a brain ventricle to the sinus system of an individual suffering from, or at risk of developing, a condition related to the retention and / or accumulation of toxic substances in the CSF, such as Alzheimer's disease. In addition to Alzheimer's disease, the present invention will be useful for treating other conditions resulting from the accumulation of toxic substances and resulting lesions in the patient's brain, such as Down's Syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch-Type (HCHWA-D), epilepsy, narcolepsy, Parkinson's disease, polyneuropathies, multiple sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophy, dystrophy myotonic, other myotonic syndromes, polymyositis, dermatomyositis, brain tumors, Guillain-Barre-Syndrome, and the like.
Owner:SINU SHUNT
Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c
InactiveUS20100330117A1Improve walking abilityImprovement in their pain functionNervous disorderSsRNA viruses positive-senseProstate cancerGuillain-Barre syndrome
The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors / Parkinson's Disease, and MS, Alzheimer's disease, ALS, Guillain-Barre syndrome, atherosclerosis, schizophrenia, Tremors / Parkinsons's disease, senile dementia, Muscular Dystrophy, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Complex Regional Pain Syndrome, Diabetes, Neuropathic Pain, Spider Arthritis West Nile Virus, Fibromyalgia, Shingles, Gout, Migraine Headaches, Post Polio Syndrome, Central Virus Deafness, Asthma, Chronic Pain Of Unknown Origin and Hepatitis C and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors / Parkinson's Disease, and prostate cancer and others realized immediate beneficial results with no side effects.
Owner:HONOR CW M D LLC
Adsorbent, preparation method thereof, and adsorption device for blood perfusion
ActiveCN105126784AReduce manufacturing costImprove efficiencyOther blood circulation devicesOther chemical processesDiseasePhosphate
The invention provides an adsorbent, a preparation method thereof, and an adsorption device for blood perfusion. The adsorbent is prepared by bonding phosphate group in DNA molecules to diazo acetic acid esterified polystyrene-divinyl benzene microspheres through covalent bonds. The preparation method comprises the following steps: preparing polystyrene-divinyl benzene microspheres, carrying out chloromethylation, carrying out alcoholization, and performing diazo acetic acid esterification to obtain the adsorbent. The adsorption device comprises the provided adsorbent. The adsorbent has a specific absorbing performance on anti-ds-DNA antibody. Through the covalent bond, the DNA can be more firmly loaded on the solid carriers, the efficiency is higher, and the DNA will not fall off from the carrier during the process of sterilization, storage, and using. The adsorbent can be applied to SLE and can also applied to autoimmune diseases such as myasthenia gravis, Guillain-Barre syndrome, rheumatoid arthritis, hypersensitive organ transplant patients, and the like.
Owner:JAFRON BIOMEDICAL
Methods of treatment for guillain-barre syndrome
InactiveUS20160326237A1Immunoglobulins against animals/humansAntibody ingredientsPhysiologyGuillain-Barre syndrome
Owner:THE UNIV COURT OF THE UNIV OF GLASGOW +1
Spirocyclic amides as cannabinoid receptor modulators
Novel compounds of structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Cb1 antagonist compounds
Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
Owner:ELI LILLY & CO
Use of bowman birk inhibitor for the treatment of multiple sclerosis and other autoimmune diseases
InactiveUS20020127289A1Reduce and inhibit and suppress and prevent chronic inflammationBiocidePeptide/protein ingredientsAutoimmune diseaseGuillain-Barre syndrome
The present invention provides a non-toxic therapy and a novel use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic inflammation, such as rheumatoid arthritis; and more particularly for the treatment of those diseases that are characterized by chronic neuroinflammation and / or demyelination, such as Multiple Sclerosis (MS) and Guillain Barre Syndrome (GBS). In addition, the present invention provides methods for using BBI / BBIC to reduce, inhibit, suppress or prevent the chronic inflammation in such patients; and more particularly, to reduce, inhibit, suppress or prevent the chronic neuroinflammation and demyelination that occurs when the patient's nerve tissue is affected by the disease.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Substituted imidazoles as cannabinoid receptor modulators
Owner:MERCK SHARP & DOHME CORP
Cb1 modulator compounds
Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
Owner:ELI LILLY & CO
Traditional Chinese medicine composition for treating neurological diseases and preparation method thereof
The invention relates to a traditional Chinese medicine composition for treating neurological diseases and a preparation method thereof, and belongs to the field of traditional Chinese medicine treatment of the neurological diseases, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-80 parts of radix astragali, 5-50 parts of radix et rhizoma asari, 5-50 parts of radix et rhizoma salviae miltiorrhizae, 5-50 parts of ramulus cinnamomi, 4-40 parts of rhizoma smilacis glabrae, 2-25 parts of radix angelicae sinensis, 3-30 parts of rhizoma chuanxiong, 2-20 parts of herba ephedrae, 3-40 parts of radix aconiti lateralis, 2-25 parts of radix paeoniae rubra, 5-40 parts of radix achyranthis bidentatae, and 5-50 parts of rhizoma anemarrhenae, the traditional Chinese medicine composition provided by the invention can be used for treating diabetic neuropathy, Guillain-Barre syndrome, sciatica, and peripheral neuritis.
Owner:SHIJIAZHUANG YILING PHARMA
Treatment of diseases caused by viral infection
InactiveUS20060018876A1Eliminate and inhibit proliferationPrevent and treat diseaseBiocidePeptide/protein ingredientsSIDS - Sudden infant death syndromeMyocarditis
A method of prophylactic and / or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and / or treat the disease in the mammal. A composition for treatment of a mammal for a disease caused by Ljungan virus infection including an antiviral compound, antiserum, and an interferon. A method of treatment of a mammal for a disease caused by a Ljungan virus infection.
Owner:APODEMUS
Substituted amides
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
CB1 antagonist compounds
Owner:ELI LILLY & CO
Nitroxides for use in treating or preventing immunological diseases
Pharmaceutical compositions are provided that are useful in treating immunological diseases. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of a gene related to an immunological disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of immunological disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl); the gene is one of glucocorticoid-induced leucine zipper, collagen type I alpha 1, and complement component 6; and the immunological disease is Graves' disease, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-independent diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformus, vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, myasthenia gravis, multiple sclerosis, Guillain-Barre syndrome, stiff-man syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic necrotizing vasculitis, Wegener's granulomatosis, antiphospholipid syndrome, Sjögren's syndrome, scleroderma, accelerated graft arteriosclerosis, graft-versus-host disease, Crohn's disease, or tuberculosis.
Owner:MATRIX BIOMED INC
Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barré syndrome:wherein R1 is hydrogen, a C1-8 alkyl group, or the like;each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like;each of R4 and R5 is hydrogen or the like; andW is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.
Owner:KYUSHU UNIV +1
Amniotic-derived peptide and uses thereof
InactiveUS20070123467A1Preventing and treating epilepsyReduce attackAntibacterial agentsPeptide/protein ingredientsGuillain-Barre syndromeLupus erythematosus
The present invention relates to the method(s) of synthesis of and the therapeutic and cosmetic applications of biologically active peptides for improving the appearance of skin, for hastening wound healing and for treating and / or preventing the progression of various conditions, injuries and diseases, including but not limited to viral hepatitis B and C, herpes zoster ganglioneuritis, diabetic peripheral polyneuropathy, nephrotic syndrome, juvenile rheumatoid arthritis, rheumatoid arthritis, psoriatic arthritis, bronchial asthma, respiratory infection, breast cancer, epilepsy, psoriasis, atherosclerosis and other forms of vascular obstructions, myocardial infarction, HIV and SARS infection, brain cell malfunction due to ischemia and trauma, pathologic consequences of ischemia-reperfusion, rejection reaction following organ transplantation, chemical and drug intoxication including but not limited to anesthetic, alcohol and morphine, cancer, type 1 diabetes mellitus, multiple sclerosis, septic shock (Gram negative sepsis), Parkinson's disease, type 2 diabetes mellitus, Alzheimer's disease, amyotrophic lateral sclerosis, hyperthyroidism, Guillain-Barre syndrome, systematic lupus erythematosus, parasitic infections, especially leishmaniasis, and other collagen diseases, and diseases in which apoptosis occurs.
Owner:BAKHUTASHVILI VLADIMER +6
Substituted amides
Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Owner:MERCK SHARP & DOHME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com